Finally, we think the clinical use of MSC obtained from the third-party donor deserve further study, as pre-clinical studies indicate that the third-party or the MHC-mismatched MSCs are immunogenic.
Patients with primary and post-essential thrombocythemiaFpolycythemia vera myelofibrosis (PMF and post-ET/PV MF)Fhave a progressive decline marked by progressive cytopenias, extramedullary hematopoiesis (manifesting as splenomegaly and/or hepatomegaly), significant constitutional symptoms, potential for blastic transformation and premature death with current therapies rarely offering more than palliative benefit. 1 We have explored many therapeutic targets in these patients including farnesyl-transferase inhibition, 2 proteosome inhibition 3 and immunomodulation with lenalidomide. 4, 5 The use of DNA hypomethylation therapy has been found to be efficacious in patients with myelodysplastic syndrome (MDS) leading to the improvement in disease-associated cytopenias, delay in transformation to acute myeloid leukemia and improved survival. 6, 7 Additionally, these agents have demonstrated activity in the myeloproliferative disorder (MPD)-MDS overlap syndrome of chronic myelomonocytic leukemia, which shares both the intrinsic proliferative phenotype of PMF and the ineffective hematopoiesis shared by MDS and PMF. 8 There are currently two federal drug administration (FDA)-approved agents in the United States of America including both 5-AZA and Decitabine (Dacogen, MGI Pharma, Bloomington, MN, USA).
Quintas-Cardama et al. 9 recently reported in Leukemia the results of a phase II trial of the DNA hypomethylation agent 5-Azacitidine (5-AZA) (Vidaza; Pharmion Boulder, CO, USA) in patients with PMF and post-ET/PV MF. This latter trial utilized the currently FDA-approved dose and schedules in patients with MDS (75 mg/m 2 subcutaneously for 7 days every 4 weeks). With this latter regimen, the authors reported limited therapeutic benefit with one patient experiencing a partial response (3%) and 21% with a clinical improvement (mainly splenomegaly) by the International Working Group for Myelofibrosis Research and Treatment criteria. Responses were generally of modest duration with a median of 4 months (range: 2-22 months) in duration.
Although 5-AZA has traditionally been administered in a 7-day (total 525 mg/m 2 /cycle) regimen, interest has remained high for a 5 day (total 375 mg/m 2 /cycle) alternative regimen to facilitate ease of administration (no weekend dosing) and hopefully less toxicity. 10 Recent results in MDS demonstrated comparable efficacy with 5-day 5-AZA in MDS. We designed and initiated a 5-day 5-AZA trial in PMF (post-PV/ET MF) to compliment the results of the trial published by QuintasCardama et al. 9 to address whether the activity observed in that latter trial would be maintained in an abbreviated dosing trial in patients with symptomatic PMF (and post-ET/PV MF).
A total of 10 patients were enrolled in this alternate dose/ schedule trial of 5-AZA in PMF (n ¼ 8) or (post-ET/PV MF (one each)). Demographic features were typical for the disorder (outlined in Table 1 ) and are very similar to those patients enrolled in the 7-day trial published by Quintas-Cardama et al.
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Therapy with the abbreviated 5-day 5-AZA was clinically ineffective for the patients with myelofibrosis, a decreased benefit as to what had been observed with the 7-day regimen. Utilizing the International Working Group for Myelofibrosis Research and Treatment response criteria, 11 no patient achieved even a clinical improvement (the minimal response recognized)
Letters to the Editor in eligible categories (neutropenia as not present at baseline based on entry criteria) including splenomegaly or anemia (see Table 2 ).
A median of three cycles was given per patient (range: 1-8), and only two patients received over three cycles of therapy. Although the goal of therapy was to administer a minimum of six cycles of treatment (based on the published need for multiple cycles to achieve response in MDS patients) early discontinuation was due to death (n ¼ 1), progression, patient choice or toxicity (see Table 2 ). The latter death was an unexpected central nervous system hemorrhage after the second cycle of 5-AZA. The platelets were normal at the time of the event, and it was felt the event occurred from a probable previously undiagnosed brain aneurysm and therefore unlikely related to the ongoing therapy with 5-AZA.
Our current description of outcomes with the 5-day 5-AZA therapy in MF reaffirms the limited benefit of this agent in this disease reported by Quintas-Cardama et al. 9 However, unlike the latter communication, we had no responses with the 5-day 5-AZA regimen in PMF (and post-ET/PV MF). These results, with the modest numbers, are contrary to MDS patients whom had similar responses with three different analyzed schedules (5 days alone; 5 days-2 days off and another 5 days; or 5 days-2 days off and then 2 more days). 10 The obvious major difference is that the median number of cycles for the MDS trials was six, as was the median number for the trial by Quintas-Cardama et al. 9 (median: 5.5 cycles, range: 2-18). Although it had been our intention to administer six or more cycle per patient in the 50-day regimen, toxicity and progression precluded that goal. Given the modest responses in the 7-day trial by Quintas-Cardama et al.
, we would speculate that this benefit may well be dose and schedule-dependent.
The urgent need for improved therapeutic options for myelofibrosis patients has led to the recently described mutations in the activation of the JAK-STAT pathway by either the JAK2 V617F and/or the MPL W515L/K mutations, which lead to downstream activation of cellular proliferation. 12 In aggregate, these mutations are present in about 50-65% of patients with PMF and post-ET -MF, and the majority are (V617F only) in post-PV -MF. Therapeutic targeting of these latter mutations are currently undergoing initial clinical testing with intriguing results, 13 with many new agents in preclinical development, which appear to be highly selective inhibitors of JAK2. 14, 15 Results of these targeted therapeutic approaches are awaited with great expectation to assess the validity of JAK2 inhibition as a therapeutic target, which will hopefully improve upon the efficacy of currently available therapies. With great interest we read the recent paper by Garcia-Manero et al. 1 who proposed a new prognostic score for patients with lower risk myelodysplastic syndromes (MDS). We agree that it is important to identify within the group of patients with low-risk and int-1-risk MDS (according to International Prognostic Scoring System (IPSS)
RA
2 ) those who actually have an inferior prognosis and, thus, should receive early treatment. This necessity has become of particular importance during the recent years due to the availability of new drugs and the improved tolerability of the current transplantation protocols.
We applied the new score to 475 patients from the Dü sseldorf MDS Registry who received best supportive care. The score successfully separated a very-low-risk group with a median survival of 80 months (n ¼ 164 and 35%), whereas no significant difference (35 vs 30 months) was observed between GarciaManero's intermediate and high-risk groups (n ¼ 257 (54%) and n ¼ 54 (11%), respectively). Relatively few patients received a high-risk score. The risk of evolution to acute myeloid leukemia (AML) within 3 years did not differ significantly between the proposed subgroups (13, 25 and 24%, respectively) (Figures 1a  and b) . In comparison, survival in the two IPSS subgroups was 70 and 31 months, respectively.
In contrast, another recently proposed scoring system, the WHO classification-based prognostic scoring system (WPSS), 3 was capable of separating the low-risk and int-1-risk patients from the Dü sseldorf MDS Registry into four risk groups that differed significantly regarding survival as well as leukemic transformation (4, 11, 23 and 37%, respectively, at 3 years) (Figures 2a and b) .
To identify confounding factors in Garcia-Manero's new score and the reasons for its inferior performance in our patient cohort, we looked at the variables included. An improvement of the new score, when compared to the IPSS, is the inclusion of hemoglobin and platelets only, as the absolute neutrophil count is not an independent prognostic parameter. The new cut-off value of 4% bone marrow blasts is interesting but should be further evaluated. In patients from our registry we could not find a significant influence on survival. This might be due to the small number of patients (12%) concerned.
The largest discrepancy that we noted, when re-analyzing Garcia-Manero's score in the Dü sseldorf MDS Registry, relates to the importance attached to platelet count, especially when compared to the importance of karyotype. In a multivariate analysis in the patients from our registry including WHO type, medullary blast count and cytogenetic risk groups according to IPSS, lactate dehydrogenase (LDH) and transfusion dependency, with or without age, platelet count did not remain an independent prognostic parameter. We have the impression that the patient population analyzed by Garcia-Manero et al., had an inferior-risk profile when compared to patients from the Dü sseldorf Registry. According to IPSS, we have 39% low-and 61% int-1-risk patients, compared to 29% low-and 71% int-1-risk patients at the MD Anderson Cancer Center. Our patients had a platelet count of less than 100 Â 10 9 /l in 34% of the cases, in contrast to 52% at MD Anderson. Only 16% of our patients had a platelet count o50 Â 10 9 /l, qualifying for the top score of 2 points in Garcia-Manero's scoring system. Although, like MD Anderson, we are a tertiary referral center for MDS patients, our
